Basit öğe kaydını göster

dc.contributor.authorKarabulut, Umut
dc.contributor.authorKeskin, Kudret
dc.contributor.authorKarabulut, Dilay
dc.contributor.authorYiğit, Ece
dc.contributor.authorYiğit, Zerrin
dc.date.accessioned2022-12-27T12:57:15Z
dc.date.available2022-12-27T12:57:15Z
dc.date.issued2022en_US
dc.identifier.citationKarabulut, U., Keskin, K., Karabulut, D., Yiğit, E. ve Yiğit, Z. (2022). Effect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction. Angiology, 73(4), 350-356. https://doi.org/10.1177/00033197211047329en_US
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.urihttps://doi.org/10.1177/00033197211047329
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10197
dc.description.abstractThe angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan and sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin have been shown to reduce rehospitalization and cardiac mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We aimed to compare the long-term cardiac and all-cause mortality of ARNI and dapagliflozin combination therapy against ARNI monotherapy in patients with HFrEF. This retrospective study involved 244 patients with HF with New York Heart Association (NYHA) class II-IV symptoms and ejection fraction <= 40%. The patients were divided into 2 groups: ARNI monotherapy and ARNI+dapagliflozin. Median follow-up was 2.5 (.16-3.72) years. One hundred and seventy-five (71.7%) patients were male, and the mean age was 65.9 (SD, 10.2) years. Long-term cardiac mortality rates were significantly lower in the ARNI+dapagliflozin group (7.4%) than in the ARNI monotherapy group (19.5%) (P = .01). Dapagliflozin [Hazard Ratio (HR) [95% Confidence Interval (CI)] = .29 [.10-.77]; P = .014] and left ventricular ejection fraction (LVEF) [HR (95% CI) = .89 (.85-.93); P < .001] were found to be independent predictors of cardiac mortality. Our study showed a significant reduction in cardiac mortality with ARNI and dapagliflozin combination therapy compared with ARNI monotherapy.en_US
dc.language.isoengen_US
dc.publisherSAGE Publications Incen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCombination Therapyen_US
dc.subjectDapagliflozinen_US
dc.subjectHeart Failureen_US
dc.subjectMortalityen_US
dc.subjectSacubitrilen_US
dc.subjectValsartanen_US
dc.titleEffect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fractionen_US
dc.typearticleen_US
dc.relation.ispartofAngiologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume73en_US
dc.identifier.issue4en_US
dc.identifier.startpage350en_US
dc.identifier.endpage356en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1177/00033197211047329en_US
dc.institutionauthorYiğit, Ece
dc.identifier.wosqualityQ3en_US
dc.identifier.wos000703105200001en_US
dc.identifier.scopus2-s2.0-85115726167en_US
dc.identifier.pmid34560822en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster